Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Launches Trial Of First-Of-A-Kind Resorbable Scaffold For Critical Limb Ischemia

Executive Summary

The Esprit BTK everolimus-eluting resorbable scaffold is designed to treat arteries below the knee. No stents or drug-coated balloons are currently FDA-approved for that indication.

You may also be interested in...



Exec Chat: Abbott Invests In Outreach To Underrepresented Populations

Jennifer Jones-McMeans, Divisional Vice President of Global Clinical Affairs at Abbott’s vascular device business, talked to Medtech Insight about her company’s ongoing efforts to diversify patient enrollment in clinical trials by communicating more effectively and compassionately with people in traditionally underrepresented demographic groups.

Abbott Wants To Expand Clinical Trial Access By Diversifying Investigator Community

The company’s plan to reduce barriers to clinical trial participation for underrepresented groups includes the creation of nearly 300 new scholarships at medical schools of historically black colleges and universities and minority nursing associations.

Start-Up Spotlight: Efemoral Begins Trial Of Peripheral Stent With Inter-Scaffold Gaps

The EFEMORAL I trial is the first-in-human study of the start-up company’s FlexStep technology in patients with symptomatic femoropopliteal artery disease.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT142698

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel